Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...

Pharmaceutical giant Novo Nordisk plans to use Denmark's first sovereign artificial intelligence supercomputer—powered by ...

While the Death Cross sends a strong bearish signal, Novo Nordisk's fundamentals paint a rosier picture. The company recently ...

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

The company has asked the FDA to convene an advisory committee to consider the matter. “Novo Nordisk’s aim with this ...

A CNBC investigation into counterfeit weight-loss drugs revealed an international illegal marketplace where criminals either alter the drugs or ship the real product from overseas.

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

DZ BANK AG analyst Elmar Kraus maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today. The company’s shares closed ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...